These therapeutic modalities promote immunogenic cell death, enhancing tumor-associated antigen presentation and stimulating the release of damage-associated molecular patterns (DAMPs), including ATP, HMGB1, and calreticulin (CRT), thereby facilitating immune cell recruitment and activation. This evidence concerns the gene HMGB1 and neoplasm.